ROCHESTER, Minnesota — A new Mayo Clinic study finds that people with Tourette syndrome have about half as many of a specific type of brain cell that helps calm overactive movement signals as people without the condition. This deficit may be a key reason why their motor signals go unchecked, leading to the involuntary tics that define the disorder.
The study, published in Biological Psychiatry, is the first to analyze individual brain cells from people with Tourette disorder. The findings also shed light on how different types of brain cells may interact in ways that contribute to the syndrome's symptoms.
"This research may help lay the foundation for a new generation of treatments," says co-author Alexej Abyzov, Ph.D., a genomic scientist in Mayo Clinic's Center for Individualized Medicine. "If we can understand how these brain cells are altered and how they interact, we may be able to intervene earlier and more precisely."
Tourette disorder is a neurodevelopmental condition that typically begins in childhood. It causes repeated, involuntary movements and vocalizations such as eye blinking, throat clearing or facial grimacing. While genetic studies have identified some risk genes, the biological mechanisms behind the condition have remained unclear.
To better understand what's happening in the brain with Tourette syndrome, Dr. Abyzov and his team analyzed more than 43,000 individual cells from postmortem brain tissue of people with and without the condition. They focused on the basal ganglia, a region of the brain that helps control movement and behavior. In each cell, they looked at how genes were working. They also analyzed how changes in the brain's gene-control systems might trigger stress and inflammation.
First, they found in people with Tourette syndrome a 50% reduction in interneurons, which are brain cells that help calm excess signals in the brain's movement circuits. They also observed stress responses in two other brain cell types. Medium spiny neurons, which make up most of the cells in basal ganglia and help send movement signals, showed reduced energy production. Microglia, the brain's immune cells, showed inflammation. The two responses were closely linked, suggesting the cells may be interacting in Tourette disorder.
"We're seeing different types of brain cells reacting to stress and possibly communicating with each other in ways that could be driving symptoms," says Yifan Wang, Ph.D., co-author of the study.
The study also provides evidence that the underlying cause of brain cell changes in Tourette disorder may be linked to parts of DNA that control when genes turn on and off.
"Tourette patients seem to have the same functional genes as everyone else but the coordination between them is broken," Dr. Abyzov says.
Next, the researchers plan to study how these brain changes develop over time and look for genetic factors that may help explain the disorder.
The study was conducted in collaboration with the lab of Flora M. Vaccarino, M.D., at Yale University. For a complete list of authors, disclosures and funding, review the study.
###
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
Media contact:
Susan Murphy, Mayo Clinic Communications, newsbureau@mayo.edu
Journal
Biological Psychiatry
Subject of Research
Not applicable
Article Title
Interneuron Loss and Microglia Activation by Transcriptome Analyses in the Basal Ganglia of Tourette Disorder
Article Publication Date
30-Jan-2025
COI Statement
This work was supported in part by a fellowship grant from the TAA (to LF) and National Institutes of Mental Health (Grant No. R01 MH118453 [to FMV]). The Harvard Brain Tissue Resource Center is supported in part by the National Institutes of Health. We acknowledge Livia Tomasini for technical advice on sample processing and the TAA for spearheading, organizing and supporting the postmortem brain collection for patients with Tourette disorder. We thank the personnel at the Harvard Brain Tissue Resource Center/National Institutes of Health NeuroBioBank for processing brain tissues and Nancy Thompson for help with the clinical phenotyping. FMV, JFL, and AA conceived the study and provided funding. FMV and AA supervised the study. JFL performed retrospective clinical phenotyping. SB, AH, and RR procured and processed postmortem brain tissue. YW, LF, TVF, and FMV designed experiments. LF performed experiments. YW, FW, MS, and TVF did bioinformatic analyses. YW generated display items and wrote the initial draft of the article. All authors provided edits and comments on the article. This study did not generate new unique reagents or DNA constructs. Datasets reported in this study are available through the National Institute of Mental Health Data Archive under collection #C3187 (https://nda.nih.gov/edit_collection.html?id=3187), study #3028 (https://nda.nih.gov/study. html?id=3028). For reasons of subjects’ privacy, as specified in our consent form, the National Institute of Mental Health Data Archive only allows for controlled access to the data. The authors report no biomedical financial interests or potential conflicts of interest.